Sonic Incytes Selected for MedTech Innovator Asia Pacific Accelerator
MedTech Innovator, the largest accelerator of medical device companies in the world, in partnership with Asia Pacific Medical Technology Association, announced on June 21 that Sonic Incytes Medical Corp. has been selected to participate in the organization’s Asia Pacific Accelerator program. Every year, MedTech Innovator selects the best and brightest medtech start-ups that are seeking […]
Watch VelacurTM in Action at Liver Connect 2021
If you’re ready to transform your liver practice, we’re ready to show you how. Discover how fast, accurate and easy VelacurTM is to assess liver health at the inaugural Liver Connect conference, April 16-17, 2021, hosted by the Chronic Liver Disease Foundation. Visit our in-person booth for live demos of Velacur, the first handheld 3D […]
Sonic Incytes Recognized as a Ready to Rocket Company For Second Year in a Row
Recognized for its growth potential, Sonic Incytes Medical Corp. has been named a top technology company in the 19th Annual “Ready to Rocket” list published by Rocket Builders. Ready to Rocket is a unique business recognition list that profiles technology companies with the greatest potential for growth. Each year, based on analysis of trends, Rocket […]
Further Studies Underway to Demonstrate Clinical Value of VelacurTM
Sonic Incytes is proud to expand its collaboration with key centers of clinical excellence in chronic liver disease in North America to continue evaluating its diagnostic solution, VelacurTM. Indiana University (IU) has recently joined Sonic Incytes’ Early Access Program to trial VelacurTM. IU aims to evaluate VelacurTM in comparison to other methods in assessing non-alcoholic […]
VelacurTM Results Presented at AASLD’s The Liver Meeting 2020
At the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting 2020, Sonic Incytes presented the results of its clinical trial using the VelacurTM prototype, a novel medical technology that measures liver elasticity and attenuation. This trial was an initial study to evaluate the ability of the VelacurTM prototype to differentiate between […]
Sonic Incytes Announces FDA Clearance and US Launch of VelacurTM to Help Manage Emerging Health Crisis
Sonic Incytes Medical Corporation is pleased to announce the US commercial release of VelacurTM, the world’s first handheld 3D liver health assessment tool with diagnostic accuracy comparable to Magnetic Resonance Imaging (MRI).
Genome BC Invests $1M in Breakthrough Solution for Detecting Chronic Liver Disease, Closing Off Sonic Incytes’ $3.5M Financing Round
Genome BC is pleased to announce $1 million in funding to Sonic Incytes Medical Corp., completing the company’s seed financing round of over CDN$3.5 million supported by institutional investors, angel funds and private individuals.
Sonic Incytes Accepted Into Boston CTA
Sonic Incytes Medical Corp. is pleased to announce it has been selected to participate in the Canadian Technology Accelerator (CTA) 2020 program, along with 10 other promising start-ups in tech and life sciences from across Canada.
Sonic Incytes Recognized as a Ready to Rocket Life Science Company
Poised for success with its breakthrough, handheld ultrasound solution for assessing and monitoring chronic liver disease, Sonic Incytes Medical Corp. has been named a top technology company in the 18th Annual “Ready to Rocket” list published by Rocket Builders today.
